Home  >  News
Eppen_Research3_6neo_Aug26
you can get e-magazine links on WhatsApp. Click here
News
  Obsidian Therapeutics enrols first patient in phase 1/2 Agni-01 study to evaluate Amsoki-cel in advanced melanoma,   August 08, 2026
  Kodiak Sciences completes enrollment in phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation,   August 08, 2026
  Dispatch Bio begins patient dosing in phase 1 study of DISP-10, a novel investigational immunotherapy, in advanced gastrointestinal cancers,   August 08, 2026
  Priovant initiates patient enrolment in phase 3 study of brepocitinib in cutaneous sarcoidosis,   August 08, 2026
  Ractigen Therapeutics completes enrollment and first dosing in phase II trial of RAG-17 for SOD1-ALS,   August 08, 2026
  Damora Therapeutics begins phase 1/1b CLARITY-101 trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis,   August 06, 2026
  Marvel Biosciences announces positive results from preclinical Fragile X study conducted through the FRAXA Drug Validation Initiative,   August 06, 2026
  4Moving Biotech completes enrollment in phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy?targeting synovitis as a driver of pain and disease progression in knee osteoarthritis,   August 05, 2026
  Evexta Bio enters clinical trial collaboration and supply agreement with Roche to evaluate rupitasertib in combo with a SERD in advanced/metastatic breast cancer,   August 05, 2026
  Otsuka unveils unprecedented phase 3 VISIONARY two-year eGFR results demonstrating Voyxact stabilizes kidney function decline to baseline physiologic rate, fundamentally altering disease progression in IgAN,   August 05, 2026
  Keenova Therapeutics announces publication of Xiaflex manuscript in Translational Andrology and Urology,   August 04, 2026
  Invenio Imaging completes enrollment in ON-SITE study, an AI-based image analysis for lung cancer,   August 04, 2026
  AusperBio begins patient dosing in clinical study of AHB-171, a siRNA therapeutic candidate for chronic hepatitis B,   August 04, 2026
  Tiziana Life Sciences announces reduction in brain inflammation in third multiple system atrophy patient treated with intranasal foralumab,   August 03, 2026
  EyePoint completes enrollment of both pivotal phase 3 trials of Duravyu to treat diabetic macular edema,   August 03, 2026
  Moleculin Biotech announces positive results from pivotal phase 2/3 MIRACLE trial of Annamycin in combo with cytarabine to treat r/r acute myeloid leukaemia,   August 03, 2026
  US FDA clears Iksuda Therapeutics’ IND application for IKS04, a CA242-directed ADC to treat patients with GI cancers,   August 01, 2026
  Atavistik Bio partners with Cure HHT Clinical Trial Network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia,   August 01, 2026
  Lokahi Therapeutics advances LT-100 development strategy toward single-injection administration,   July 31, 2026
  Pfizer reports positive topline phase 3 results for Litfulo in patients with nonsegmental vitiligo,   July 31, 2026

  • Results Found: 17155
  • 1
    •  
  • 2
    •  
  • 3
    •  
  • 4
    •  
  • 5
    •  
  • Go to
  • Total Number of Pages: 858
 Back
 
NPME-2026
cphi_korea2026
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram